Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      dsm-firmenich reports H1 2024 results


      News provided by

      dsm-firmenich

      30 Jul, 2024, 05:00 GMT


      This image opens in the lightbox
      View PDF
      dsm-firmenich
      This image opens in the lightbox
      dsm-firmenich logo (PRNewsfoto/dsm-firmenich)

      KAISERAUGST, Switzerland and MAASTRICHT, Netherlands, July 30, 2024 /PRNewswire/ -- 

      Management Report

      H1 2024 highlights

      • Strong improvement of financial results
      • Synergies and vitamin transformation program on track, with €95 million delivered in the first six months
      • Mid-term strategy defined, including financial targets and sustainability ambitions
      • Portfolio fine-tuning progressing with divestments of yeast extracts and marine lipids already announced
      • Animal Nutrition & Health separation well advanced
      • FY 2024 outlook increased: Adjusted EBITDA around €2 billion

      Key figures


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      6,298

      6,152

      2

      3,227

      3,030

      7

      Organic sales growth (%)

      4



      7



      Adj. EBITDA

      976

      929

      5

      513

      408

      26

      Adj. EBITDA margin (%)

      15.5

      15.1


      15.9

      13.5


      Core adj. net profit

      365

      236

      55




      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Key figures on an IFRS basis


      in € millions

      H1 2024

      H1 2023²

      % Change

      Sales

      6,298

      4,470

      41

      Net profit (total group)

      50

      2,375

      (98)


      2 Represents the figures on an IFRS basis, including the Firmenich results as of the merger date May 8, 2023.

      Dimitri de Vreeze, CEO, commented: "We are pleased with our achievements in the first six months of the year. We launched our strategic plan at our capital markets day in June and are making good progress with the synergies and vitamin transformation programs. The separation of the Animal Nutrition & Health business is well underway, and we already announced two divestments as part of our portfolio fine-tuning. 

      At the same time, our relentless focus on operational excellence, combined with improving business conditions, resulted in better financial results. Perfumery & Beauty and Taste, Texture & Health both delivered a strong performance. Health, Nutrition & Care and Animal Nutrition & Health saw improved momentum.

      We upgrade our full year outlook to around €2 billion based on the positive business momentum continuing into the third quarter and our commitment to deliver a €200 million Adjusted EBITDA contribution from a combination of synergy delivery and the vitamin transformation program, while we should remain cautious about the general economic conditions in which our customers operate."

      Outlook 2024

      The company increases its outlook and expects an Adjusted EBITDA of around €2 billion in FY 2024.

      Strategy

      At its capital markets day in Paris on June 3, 2024, dsm-firmenich defined its strategy to better leverage its unique portfolio and capabilities to further strengthen its position as a global leader in nutrition, health, and beauty, maximizing the synergistic potential of the merger.

      The company will focus on its consumer activities after having announced plans to separate the Animal Nutrition & Health business from the Group. It will further fine-tune its consumer activities by deprioritizing certain activities, totaling more than €600 million in annual sales. To date, the company has already announced the sale of two of these activities, representing about €300 million in annual sales: the yeast extract business to Lesaffre and the marine lipids business to KD Pharma Group.

      With these strategic actions, the company wants to accelerate its innovation-led growth by prioritizing the high-growth and high-margin segments of Perfumery & Beauty (P&B), Taste, Texture & Health (TTH) and Health, Nutrition & Care (HNC), with the following mid-term financial targets for dsm-firmenich in its new scope:

      • Organic Sales Growth: 5-7%
      • Adjusted EBITDA margin: 22-23%
      • Cash-to-sales conversion: >10%

      By operating as a "Category of One", with a strong focus on science and sustainability and our innovation and creation-led approach, dsm-firmenich seeks to create what is essential for life as well as desirable for consumers yet simultaneously more sustainable for the planet. Working closely with customers, dsm-firmenich is poised to bring progress to life for billions of people around the world.

      Delivering synergies through integration

      dsm-firmenich is on track to achieve its target synergies of approximately €350 million Adjusted EBITDA per year. Around half of this is expected to come from cost efficiencies, with the full run rate achieved by the end of year 3. The remaining synergies are expected from incremental revenues of €500 million, generated by an acceleration of innovation with customers, with the full run rate expected by the end of year 4. These revenue synergies are driven by complementary capabilities and realized in all three business units of the Group's new scope with roughly the following balance:

      • 60% in TTH
      • 25% in HNC
      • 15% in P&B

      In the first six months of this year, synergies contributed around €50 million to Adjusted EBITDA and dsm-firmenich expects to realize about €100 million for full year 2024.

      Vitamin transformation program

      Mid-2023, the company embarked on a major restructuring program in its vitamin activities to reduce costs and restore profitability. This program is expected to result in an estimated Adjusted EBITDA contribution of around €200 million per year with the full run rate to be reached by the end of 2024. These savings will be in addition to the previously announced €350 million Adjusted EBITDA synergies target. Neither of these targets will be disrupted by the separation of Animal Nutrition & Health. dsm-firmenich has already made strong progress in executing the program by closing the Vitamin B6 and Vitamin C plants in China and optimizing the premix sites, creating a more focused and agile organization model.

      In the first six months of 2024, the program generated a contribution of about €45 million to Adjusted EBITDA. For full year 2024, dsm-firmenich expects to achieve a contribution of around €100 million to Adjusted EBITDA.

      Separation of Animal Nutrition & Health from the Group

      In February 2024, dsm-firmenich announced its intention to separate the Animal Nutrition & Health business from the company, having concluded a different ownership structure would best realize its full potential. Furthermore, through this process, the company would reduce its exposure to vitamins earnings volatility and reduce its capital intensity, in line with its newly defined long-term strategy.

      Since then, the company has selected the team charged with preparing and executing the separation. The deal perimeter has been established together with the operational separation blueprint. The company expects to announce a transaction in the course of 2025.

      Key figures and indicators

      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Net sales

      6,298

      6,152

      2

      3,227

      3,030

      7

      P&B

      2,007

      1,875

      7

      1,021

      903

      13

      TTH

      1,632

      1,533

      6

      834

      761

      10

      HNC

      1,091

      1,144

      (5)

      565

      562

      1

      ANH

      1,536

      1,571

      (2)

      790

      786

      1

      Corporate

      32

      29

      10

      17

      18

      (6)

      Adj. EBITDA 

      976

      929

      5

      513

      408

      26

      P&B

      454

      379

      20

      220

      169

      30

      TTH

      309

      289

      7

      159

      137

      16

      HNC

      173

      220

      (21)

      94

      100

      (6)

      ANH

      87

      85

      2

      63

      17

      271

      Corporate

      (47)

      (44)

      7

      (23)

      (15)

      53

      Adj. EBITDA margin (%)

      15.5

      15.1


      15.9

      13.5


      P&B

      22.6

      20.2


      21.5

      18.7


      TTH

      18.9

      18.9


      19.1

      18.0


      HNC

      15.9

      19.2


      16.6

      17.8


      ANH

      5.7

      5.4


      8.0

      2.2


      Adj. EBIT

      381

      417

      (9)











      Core adj. EBIT

      525

      459

      14




      Core adj. net profit

      365

      236

      55











      Average number of shares (x millions)

      265.0

      265.2





      Core adj. EPS

      1.35

      0.87












      (Avg.) core capital employed

      16,157

      16,427





      Core adj. ROCE (%)  

      6.5

      5.6












      Operating working capital

      3,968

      4,089





      Capital expenditures (cash)

      337

      348





      Adj. gross operating free cash flow

      460

      285






      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Key figures and indicators on an IFRS basis


      in € millions

      H1 2024

      H1 2023²

      % Change

      Net sales

      6,298

      4,470

      41

      EBITDA

      846

      317

      167

      EBITDA margin (%)

      13.4

      7.1


      EBIT

      157

      (371)

      (142)

      Net profit (total group)

      50

      2,375


      Basic EPS (total group)

      0.16

      11.77






      Effective tax rate (%)

      26.0

      27.7


      Net debt

      3,449

      1,831


      Workforce (headcount)

      27,926

      29,306



      2 Represents the figures on an IFRS basis, including the Firmenich results as of the merger date May 8, 2023.

      dsm-firmenich H1 2024 and Q2


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      6,298

      6,152

      2

      3,227

      3,030

      7

      Organic sales growth (%)

      4



      7



      Adj. EBITDA

      976

      929

      5

      513

      408

      26

      Adj. EBITDA margin (%)

      15.5

      15.1


      15.9

      13.5



      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      H1 2024 

      • Strong performance of Perfumery & Beauty (P&B)
      • Good performance of Taste, Texture & Health (TTH)
      • Gradually improving business conditions for Health, Nutrition & Care (HNC)
      • Increased profitability for Animal Nutrition & Health (ANH)

      The company saw the overall business momentum improving during the first half. P&B had a strong performance throughout the entire period. TTH saw demand accelerating throughout the first half. HNC saw destocking effects fading with demand for dietary supplements picking up in the second quarter. ANH started to benefit from improved profitability in vitamins from Q2.

      Adjusted EBITDA was up 5% with a contribution of €95m from the vitamin transformation program and cost synergies. The Adjusted EBITDA was still impacted by a negative vitamin effect, estimated at €65 million, and by negative foreign exchange effects estimated at about €25 million. The Adjusted EBITDA margin was 15.5%.

      Gross free cash flow amounted to €460 million in H1, showing a 61% improvement versus the prior year. Inventories came down versus the prior year, despite ensuring sufficient stock levels to support an improving business momentum.

      Q2 2024

      • Very strong growth in P&B, including good contribution from recovery in Ingredients
      • Strong performance of TTH
      • HNC returned to volume growth on higher demand for dietary supplements
      • Significantly improved results in ANH with strong growth in Performance Solutions and higher vitamin profitability

      The second quarter saw P&B delivering exceptionally strong results across all its three business lines, with a good recovery in demand for Ingredients. TTH saw a further acceleration following a good first quarter, driven by higher demand for both Taste and Ingredient Solutions. HNC benefited from an improvement in demand for dietary supplements, while Early Life Nutrition saw continued customer destocking. In ANH, Performance Solutions delivered another strong quarter, while profitability in vitamins started to improve.

      Adjusted EBITDA was up 26% with a contribution of €50 million from the vitamin transformation program and cost synergies. The Adjusted EBITDA included a negative foreign exchange effect, estimated at about €10 million, compensated by improved vitamin profitability, estimated at about €15 million. The Adjusted EBITDA margin was 15.9%.

      Business Unit Review

      Perfumery & Beauty 

      Perfumery & Beauty (P&B) is the leading creation and innovation partner for the most iconic global and local brands in consumer goods, lifestyle, and luxury beauty. The business unit is home to some of the best talent in the industry, boasts an unmatched palette of captive ingredients, and is supported by a vertically integrated supply chain. Powered by our science-based innovations in Fragrance and Beauty & Care, we make our customers' products more desirable, essential, and sustainable, driving consumers' preference.

      Business unit results


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      2,007

      1,875

      7

      1,021

      903

      13

      Organic sales growth (%)

      7



      13



      Adj. EBITDA

      454

      379

      20

      220

      169

      30

      Adj. EBITDA margin (%)

      22.6

      20.2


      21.5

      18.7



      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Sales and Adjusted EBITDA

      H1 2024

      P&B delivered strong financial results in the first half, with strong demand across its three segments and supported by a newly redesigned organization, better aligned to serve customers. The business delivered organic sales growth of 7%, with 10% higher volumes (including a 2% negative effect from the Pinova plant closure). Lower pricing (-3%) resulted from product mix effects and some pass-through of lower input costs.

      Strong demand for Perfumery and Beauty & Care resulted in an excellent performance in the first six months of the year. Ingredients saw a gradual improvement of the results through the period with demand recovery.

      In the first half, P&B launched several new innovations across its three segments. Perfumery launched PopScent® Clear for laundry care, combining the most advanced malodor-neutralizing technologies with encapsulation. It also added two new Haloscent® patented profragrance molecules giving an amplified fragrance effect, specifically designed for fine fragrance and hair care products. Beauty & Care experienced momentum in innovation with the launch of Eterwell™ Youth, an award-winning, holistic solution for healthy ageing skin, acting on the cellular level and efficient on any skin type, clearing senescent (zombie) cells. Ingredients launched the Sharing Innovation 2024 collection, featuring CLEARWOOD® PRISMA, a new captive ingredient made through biotechnology, which is 100% natural, 100% renewable and biodegradable.

      Adjusted EBITDA was up 20%, driven by higher demand, contribution of synergies, and lower input costs. The Adjusted EBITDA margin was up 240 bps to 22.6%.

      Q2 2024

      P&B delivered organic sales growth of 13%, with 17% higher volumes (including a 2% negative effect from the Pinova plant closure), partly offset by 4% lower pricing from product mix effects and some pass-through of lower input costs.

      P&B delivered an exceptionally strong result with double digit volume growth across all three business lines. Perfumery recorded continued good growth in Fine Fragrances, while demand for Consumer Fragrances was exceptionally strong, driven by a catch-up effect after destocking last year and customer preference for higher product superiority. Ingredients saw a strong demand in the quarter across all end-use segments. Beauty & Care saw continued positive momentum for both its beauty actives and for its hair, skin, and sun offerings, supported by sales synergies originating from the support of Perfumery. Adjusted EBITDA was up 30%, driven by higher volumes, lower costs, and the contribution from synergies. The Adjusted EBITDA margin was up 280 bps to 21.5%, supported by strong sales in the quarter, but somewhat impacted by negative product mix effects and one-off costs.

      Taste, Texture & Health

      Taste, Texture & Health (TTH) brings progress to life by tackling some of society's biggest challenges: providing nutritious, healthy and sustainable food and beverages, and accelerating the diet transformation with appealing taste and texture, and nourishing a growing global population whilst minimizing food loss and waste. TTH consists of Taste, which includes flavors, natural extracts, sugar reduction solutions, and Ingredients Solutions, which includes food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins.

      Business unit results


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      1,632

      1,533

      6

      834

      761

      10

      Organic sales growth (%)

      8



      11



      Adj. EBITDA

      309

      289

      7

      159

      137

      16

      Adj. EBITDA margin (%)

      18.9

      18.9


      19.1

      18.0



      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Sales and Adjusted EBITDA

      H1 2024

      TTH saw a good market recovery after the destocking in 2023 and recorded 8% organic sales growth in the first six months of the year with 8% volume growth on good demand in both Taste and Ingredient Solutions across all regions and account categories. Prices were stable.

      In the first six months, TTH launched several innovations, already seeing take up from customers. In the Sugar reduction platform, the business added carbonation modulation to its toolbox. This innovation helps increase consumer perception of CO2 in sugar-reduced drinks while reducing CO2 content, which in turn helps reducing the thickness of plastic bottles. The business also launched Novasense Alcohol Modulation. This technology replicates the sensation of alcohol in light or non-alcoholic drinks and has seen already some early adoptions by producers of non-alcoholic beer. Additionally, TTH enriched its portfolio of best-in-class milk solutions with new vegan dairy-like flavors. These include Dynarome® DA, the latest technology to replicate milk mouthfeel and mask plant-based off-notes to deliver a superior dairy experience for milk analogs. Finally, TTH launched its latest automated antibiotic residue test, Delvotest® Go, with user-friendly features supporting the dairy value chain to become more sustainable by preventing milk waste and ensuring that dairy products contain less antibiotics.

      The Adjusted EBITDA was up 7% with a strong step-up in the second quarter due to higher volumes and the contribution from synergies. The Adjusted EBITDA margin was flat at 18.9%.

      Q2 2024

      TTH had a strong quarter with 11% organic growth. Volumes rose 12% with double digit growth in both Taste and Ingredient Solutions, on strong customer demand driven by catch-up effects after destocking last year and with the first benefits from sales synergies. Pricing (-1%) was broadly stable.

      The Adjusted EBITDA was up 16% driven by the strong volume growth and the benefit from synergies. The Adjusted EBITDA margin was up 110bps to 19.1%.

      Health, Nutrition & Care

      Health, Nutrition & Care (HNC) enables people to improve their health by supplementing their diet with critical nutrients and driving medical innovation forward, so helping to optimize immunity, speed up recovery and enhancing quality of life.

      Business unit results


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      1,091

      1,144

      (5)

      565

      562

      1

      Organic sales growth (%)

      (4)



      1



      Adj. EBITDA

      173

      220

      (21)

      94

      100

      (6)

      Adj. EBITDA margin (%)

      15.9

      19.2


      16.6

      17.8



      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Sales and Adjusted EBITDA

      H1 2024

      HNC had a slow start to the year driven by negative vitamin effects and continued destocking. The business saw a gradual improvement in demand through the period. Overall, HNC reported -4% organic sales with volumes and price contributing in equal parts in the first six months.

      In the first six months, HNC saw a very strong uptake for its algal omega-3 oils across all segments supported by the value proposition of a pure, clean, highly sustainable, and twice as concentrated algal omega-3 portfolio. In addition, HNC obtained important regulatory approvals for key ingredients during the period, e.g., for ampli-D from EFSA in Europe. The business also launched both in Europe and Asia the first "biotic" vitamin (i.e., reaching the colon), Humiome B2, which is gaining good traction. Specifically for early life nutrition, customers in China have launched the first products containing HMOs in stage-4 infant formulas. HNC expects further progress in China for the other infant formula categories in H2. i-Health very successfully launched several new products in the health from the gut space, such as Culturelle Weight Management and Bloating & Gas Defense and Estroven Weight Management.

      Adjusted EBITDA was down 21%, as the contributions from the cost synergies and the vitamin transformation program were offset by a negative vitamin effect, which is estimated at €30 million, and by a negative foreign exchange effect, estimated at around €15 million. This resulted in an Adjusted EBITDA margin of 15.9%.

      Q2 2024

      HNC saw organic sales growth turning positive (+1%), with 2% volume growth. Business conditions for dietary supplements improved throughout the quarter. The volume growth in this segment was still largely offset by ongoing destocking in early life nutrition. i-Health performed well in the quarter. Overall, pricing (-1%) was stable.

      Adjusted EBITDA was down 6% as the positive contribution from volume growth, cost synergies and the vitamin transformation program was more than offset by higher costs (especially for fish oils) and negative foreign exchange effects. This was reflected in the 120bps contraction in the Adjusted EBITDA margin to 16.6%.

      Animal Nutrition & Health

      Animal Nutrition & Health (ANH) helps delivering healthy animal proteins efficiently and sustainably, whilst harnessing the power of data to make animal farming practices more sustainable, productive, and transparent.

      Business unit results


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      1,536

      1,571

      (2)

      790

      786

      1

      Organic sales growth (%)

      (1)



      2



      Adj. EBITDA

      87

      85

      2

      63

      17

      271

      Adj. EBITDA margin (%)

      5.7

      5.4


      8.0

      2.2


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Sales and Adjusted EBITDA

      H1 2024

      Organic sales in H1 were broadly in line with prior year (-1%). The business returned to volume growth (+3%) with strong growth in Performance Solutions and solid growth in premix. Vitamin volumes remained soft. Prices were down 4% due to lower vitamin prices in the first quarter, while in the second quarter, lower pricing was the result of mix effects.

      Overall, demand for animal protein remained robust, though the swine industry in China remained under pressure, with sow herds down 7%, together with weak farm economics in the region. Poultry continued to show a healthy demand, while Ruminant demand returned to growth.

      Adjusted EBITDA was up 2%. The performance increased significantly over the first half with strong organic growth in Performance Solutions, lower input costs, and the contribution from the cost synergies and the vitamin transformation program. This was partly offset by a negative foreign exchange effect, estimated at €5 million. The residual negative vitamin effect is estimated at €35 million. The Adjusted EBITDA margin was 5.7%.

      Q2 2024

      The quarter saw a significant improvement in profitability from lower costs, supported by the continued strong performance of Performance Solutions. Organic growth (+2%) turned positive in the quarter driven by volumes (+4%) from strong growth in Performance solutions, a solid growth in premixes, and limited growth from vitamins. Lower pricing (-2%) was the result of mix effects in the quarter with vitamin prices being overall stable.

      Adjusted EBITDA increased to €63 million, driven by volume growth, including about €20 million from the cost synergies and the vitamin transformation program, and about €15 million from improved vitamin profitability. The Adjusted EBITDA margin was 8%.

      Corporate activities


      in € millions

      H1 2024

      Pro forma
      H1 2023¹

      % Change

      Q2 2024

      Pro forma
      Q2 2023¹

      % Change

      Sales

      32

      29

      10

      17

      18

      (6)

      Adj. EBITDA

      (47)

      (44)


      (23)

      (15)


      1 Represents the figures on a pro forma basis, including the Firmenich results as if the merger had occurred as of the beginning of the year. The pro forma figures represent the results from continuing operations - please also refer to the section Definitions.

      Corporate activities have been stable in H1 versus last year. The reported Adjusted EBITDA typically shows some fluctuations, but they do not reflect a change in overall cost levels.

      Cash Flow and Working Capital

      Cash Flow and Working Capital


      in € millions


      H1 2024

      Pro forma
      H1 2023

      Adj. gross operating free cash flow

      460

      285




      Operating working capital (OWC)

      3,968

      4,089

      OWC as % of sales - end of period

      30.7

      33.7

      Total working capital (WC)

      3,280

      3,321

      Total WC as % of sales - end of period

      25.4

      27.4

      In the first six months of the year, the Adjusted gross operating free cash flow was up €175 million versus prior year, representing a cash conversion ratio of 7% on Sales. OWC improved to 30.7% of Sales from 33.7% in prior year, reflecting discipline in managing operational efficiency and continued commitment to progress on our cash ambitions.

      Alternative Performance Measures (APMs)

      The policy on Alternative Performance Measures (APMs) and a reconciliation between the APMs and the most directly reconcilable IFRS metric can be found in Note 2 to the Condensed consolidated interim financial statements.

      In the first six months of the year, the main APM adjustments were: 

      • Acquisition (merger) and divestments costs of €86 million, mainly related to integration costs from the merger of DSM and Firmenich, and the sale of the Jiangshan Vitamin C business
      • Restructuring costs of €44 million, mainly related to the vitamin transformation program
      • Impairments of Property, Plants and Equipment (PPE), goodwill, and intangible assets of €94 million, mainly related to the impairment of the Marine Lipids business

      Sustainability

      Early in the year, dsm-firmenich launched its renewed sustainability program People.Planet.Progress. focusing on six themes in People and Planet.

      People

      Planet

      Fuel healthy lives

      Accelerate climate action

      Empower people to thrive

      Safeguard nature and biodiversity

      Nurture well-being

      Conserve our planet's resources

      The company advances its sustainability ambition through its products, services, and solutions; and through how it creates, sources, and delivers. Through these six themes, dsm-firmenich brings progress to life by combining the essential, the desirable and the sustainable. A full set of commitments linked to the focus areas will be published in early 2025.

      People



       H1 2024 

      2023

      Safety



      Frequency index of recordable incidents - all

      0.28

      0.31




      Engagement



      Employee Engagement

      80 %

      82 %

      Value Awareness

      83 %

      77 %

      dsm-firmenich is committed to fostering a world where people are healthy, well-nourished, where they thrive and feel well. In the first half of 2024, the company launched its Life Saving Rules, the Diversity, Equity and Inclusion policy, and a network of Mental Health First Aiders demonstrating its commitment to deliver a safe and inclusive work environment. The company took further steps in closing the micronutrient gap through several initiatives, including, among others, by participating in Millers for Nutrition and continuing the partnership with World Vision, and improving diversity and inclusion in the beauty industry through the new partnership with The Colors.

      The January Employee Engagement Survey received a 79% response rate, providing insight into how employees are feeling and where the company needs to make improvements. Workplace engagement remained high at 80%, with employees remaining hopeful, curious and excited about the ongoing integration. Recognition of the company values increased, with 83% of employees stating that they recognize and embrace the values, while 89% of employees feel their contributions significantly impact the company's customers. The survey identified improvement areas on transparency, uncertainty, and inclusion. To address this, the company has focused on these areas in employee communications and leadership programs, and developed Business-unit- and function-specific plans and targets on DEI.

      Planet



       H1 2024 

      2023

      GHG Absolute reduction versus 2021¹



      Scope 1 and 2²

      21 %

      -

      Purchased renewable electricity

      92 %

      88 %

      1 Our science-based targets (pending SBTi validation) were launched in late 2023. This is the first period of reporting progress, so no comparative information is available.

      2 Under scope 3, our H1 2024 over 2021 category 1 emission intensity has reduced by approximately 5 %. Absolute reduction will be reported for full year 2024.

      The company takes its responsibility to accelerate climate action, as climate change is the most pressing environmental issue. In early 2024, dsm-firmenich submitted science-based targets for validation by the Science Based Targets initiative (SBTi), aiming to achieve net-zero by 2045, aligned with the ambition of keeping global warming below 1.5°C. The company's mid-term targets consist of an absolute emission reduction of 42% for Scope 1 and 2, and 25% for Scope 3, by 2030 from a 2021 baseline, without the use of carbon offsets, as well as a target to reach 100% purchased renewable electricity by 2025.

      dsm-firmenich delivered good progress on its GHG reduction program. Approximately 50 projects that were implemented in 2023 contributed to GHG emissions reductions such as compressor optimization, boiler efficiency improvements, steam distribution improvements and steam generation from reactor heat. The increased share of purchased renewable electricity was due to a new renewable electricity contract in China, combined with an overall reduction in electricity demand. Within Scope 3, reductions are driven by emissions reduction delivered by our suppliers and optimizing our product/supplier mix. Driven by our Supplier Engagement Program, we now have 25% of our spend covered by our suppliers who have set SBTi targets, aligning with our ambition. The company also implemented projects on waste valorization, water savings, and other energy savings.

      Progress

      In the first half of 2024, dsm-firmenich was rated as having low ESG risk from Sustainalytics. It also maintained its AAA MSCI rating and its Prime rating from ISS. This places dsm-firmenich in the top decile of its industry for these ratings. Furthermore, dsm-firmenich maintained its listing as a constituent company in the FTSE4Good Index series. This Index was the first joint listing that dsm-firmenich received.

      The company launched its Responsible Sourcing standard during the supplier event "Join Forces for Responsible Sourcing". The Standard outlines the company's engagement framework for suppliers and addresses both expectations of, and opportunities for, suppliers who engage with dsm-firmenich. From a supply chain due diligence perspective, the company continually screens its supply chains for potential or actual adverse impacts, and defines and implements action plans to cease, prevent or mitigate these impacts. More information on the due diligence approach can be found in the company's first Human rights report.

      Definitions

      This press release includes information that is presented in accordance with IFRS as issued by the International Accounting Standard Board and alternative performance measures (APMs). Please refer to the section below for the definitions as applied. The comparatives in the management report to this press release contain information that is presented on a pro forma basis ('pro forma'), which includes the Firmenich results as if the merger had occurred on January 1, 2022. The pro forma figures represent the results from continuing operations – please also refer to the Integrated Annual Report 2023.

      Alternative Performance Measures (APMs)

      In monitoring the financial performance of dsm-firmenich, management uses certain Alternative performance measures (APMs) not defined by IFRS. These APMs should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. APMs do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.

      To arrive at the Alternative Performance Measures (APMs) Adjusted EBITDA, Adjusted EBIT, and Adjusted net profit, adjustments are made for material items of income and expense arising from circumstances such as acquisitions and divestments, restructuring, impairments and other events (i.e., APM adjustments). Other APM adjusting events include site closure costs, environmental cleaning, litigation settlements or other non-operational (contractual) arrangements. Other than items related to acquisition and integration costs incurred in the first year from the acquisition date (including non-recurring inventory value adjustments) as well as adjustments due to previously recognized APM adjusting events, the threshold is €10 million.

      The APMs used throughout this press release are:

      Organic sales growth (OSG)

      Organic sales growth is the sales growth excluding the impact of acquisitions, divestments, and currency impacts.

      Earnings before interest, tax, depreciation and amortization (EBITDA) 

      EBITDA is defined as IFRS metric operating profit plus depreciation, amortization, and impairments.

      Adjusted earnings before interest, tax, depreciation and amortization (Adj. EBITDA) 

      Adjusted EBITDA is the EBITDA adjusted for material items of profit or loss, as defined under 'APM adjustments'.

      EBITDA margin

      EBITDA margin is EBITDA expressed as a percentage of net sales.

      Adjusted EBITDA margin (Adj. EBITDA margin)

      Adjusted EBITDA margin is adjusted EBITDA expressed as a percentage of net sales.

      Adjusted operating profit (Adj. EBIT)

      Adjusted operating profit (Adj. EBIT) is the IFRS metric operating profit adjusted for material items of profit or loss, as defined under 'APM adjustments'.

      Core adjusted EBIT (Core adj. EBIT)

      Core adjusted EBIT is calculated as the IFRS metric operating profit adjusted for material items of profit or loss, as defined under 'APM adjustments', and adjusted for the impact of the Firmenich purchase price allocation (PPA).

      Adjusted net profit (Adj. net profit)

      Adjusted net profit is the IFRS metric net profit adjusted for material items of profit or loss, as defined under 'APM adjustments'.

      Core adjusted net profit (Core adj. net profit)

      Core adjusted net profit is the IFRS metric net profit (from continuing operations) adjusted for material items of profit or loss, as defined under 'APM adjustments', and adjusted for the impact of the Firmenich purchase price allocation (PPA).

      Adjusted gross operating free cash flow (AGOFCF)

      Adjusted gross operating free cash flow (AGOFCF) is defined as the IFRS metric operating profit plus depreciation, amortization, and impairments, adjusted for material items of profit or loss, as defined under 'APM adjustments', corrected for changes in the working capital, minus capital expenditures. This metric is based on continuing operations.

      Adjusted earnings per share (Adj. EPS)

      Adjusted earnings per share (Adjusted EPS) is calculated as the net profit available to holders of ordinary shares adjusted for material items of profit or loss, as defined under 'APM adjustments', divided by the average number of ordinary shares outstanding.

      Core adjusted earnings per share (Core adj. EPS)

      Core adjusted earnings per share (Core adjusted EPS) is calculated as the net profit (from continuing operations) available to holders of ordinary shares adjusted for material items of profit or loss, as defined under 'APM adjustments', and adjusted for the impact of the Firmenich purchase price allocation (PPA), divided by the average number of ordinary shares outstanding.

      Capital employed

      Capital employed is the total of the carrying amount of intangible assets and property, plant and equipment, inventories, trade receivables and other receivables, less trade payables, other current liabilities, investment grants and customer funding. Average capital employed is calculated as the average of the capital employed at the end of the preceding five quarters, including the current quarter.

      Core capital employed

      Core capital employed is defined as capital employed, adjusted for the impact of the Firmenich purchase price allocation (PPA). Average core capital employed is calculated as the average of the core capital employed at the end of the preceding five quarters, including the current quarter.

      Return on capital employed (ROCE)

      Return on capital employed (ROCE) is the adjusted operating profit (from continuing operations) as a percentage of average capital employed.

      Core adjusted return on capital employed (Core adj. ROCE)

      Core adjusted return on capital employed (Core adj. ROCE) is core adjusted EBIT as a percentage of average core capital employed.

      Operating working capital

      The total of inventories and trade receivables, less trade payables.

      Capital expenditures (CAPEX)

      Capital expenditures include all investments in intangible assets and property, plant and equipment.

      Net debt

      Net debt is the total of current and non-current borrowings less cash and cash equivalents, current investments and the net position of derivatives.

      Statement of the Board of Directors

      This document represents dsm-firmenich's half yearly report containing the management report as well as the condensed consolidated interim financial statements for the purpose of the Dutch Act on Financial Supervision (Wet Financieel Toezicht), section 5:25d.

      Per the Dutch Decree on Transparency for issuing entities subject to the Dutch Act on Financial Supervision (Besluit Transparantie uitgevende instellingen Wft) article 10, the Directors declare that, to the best of their knowledge:

      • The condensed consolidated interim financial statements have been prepared in accordance with IAS 34 'Interim Financial Reporting' as issued by the international Accounting Standards Board
      • The interim management report gives a fair review of important events during the first six months of the financial year that impact the Company's business.

      Thomas Leysen, Chairman of the Board of Directors

      Dimitri de Vreeze, Chief Executive Officer

      Condensed consolidated interim financial statements H1 2024

      Condensed consolidated interim income statement



      H1 2024

      H1 2023

      Continuing operations



      Net sales

      6,298

      4,470

      Gross profit

      2,184

      1,408

      Operating profit

      157

      (371)

      Financial income and expense

      (46)

      (77)

      Profit before tax

      111

      (448)

      Income tax expense

      (59)

      36

      Share of net profit of associates and joint ventures

      (2)

      -

      Net profit from continuing operations

      50

      (412)

      Net profit from discontinued operations

      -

      2,787

      Net profit for the period

      50

      2,375

      Attributable to: 



      - Holders of shares

      42

      2,361

      - Non-controlling interests

      8

      8

      - Dividend on cumulative preference shares

      -

      6




      Earnings per share (EPS) total (in €):



      - Basic EPS

      0.16

      11.77

      - Diluted EPS

      0.16

      11.76




      Earnings per share (EPS) continuing operations (in €):



      - Basic EPS

      0.16

      (2.12)

      - Diluted EPS

      0.16

      (2.12)

      Condensed consolidated interim statement of comprehensive income


      in € millions

      H1 2024

      H1 2023

      Net profit for the period

      50

      2,375

      Other comprehensive income



      Remeasurements of defined benefit liability

      53

      (19)

      Change in fair value reserve

      4

      (24)

      Exchange differences on translation of foreign operations relating to non-controlling interests

      -

      (7)

      Related tax

      (10)

      4

      Items that will not be reclassified to profit or loss

      47

      (46)




      Exchange differences on translation of foreign operations

      (87)

      (153)

      Change in hedging reserve

      (18)

      10

      Equity accounted investees - share of other comprehensive income

      (1)

      4

      Related tax

      3

      -

      Items that may subsequently be reclassified to profit or loss

      (103)

      (139)




      Total comprehensive income for the period, net of tax

      (6)

      2,190

      Condensed consolidated interim statement of changes in equity


      x € millions

      Share
      capital

      Share
      premium

      Treasury
      shares

      Other
      reserves

      Retained
      earnings

      Shareholders'
      equity

      Non-contr.
      interests

      Total
      Equity

      Balance at January 1, 2023

      328

      471

      (196)

      363

      9,777

      10,743

      102

      10,845

      Total comprehensive income

      -

      -

      -

      (178)

      2,367

      2,189

      1

      2,190

      Dividend

      -

      (424)

      -


      (158)

      (582)

      -

      (582)

      Options / performance shares granted

      -

      -

      -

      10

      -

      5

      -

      5

      Options / performance shares vested /
      canceled 

      -

      -

      -

      (5)


      -

      -

      -

      Repurchase / cancellation of shares

      (67)

      (2)

      89

      -

      (277)

      (257)

      -

      (257)

      Transfer minority shareholding DSM B.V. from
      equity to liability

      (10)

      (18)

      -

      -

      (597)

      (625)

      -

      (625)

      Issue new shares (including swap DSM N.V. into
      DSM-Firmenich AG)

      (248)

      11,729

      -

      -

      -

      11,481

      -

      11,481

      Reissued shares

      -

      -

      55

      -

      (34)

      21

      -

      21

      Changes in non-controlling interests

      -

      -

      -

      -

      -

      -

      44

      44

      Remuneration on deeply subordinated fixed
      rate resettable perpetual notes

      -

      -

      -

      -

      -

      -

      -

      -

      Other changes

      -

      -

      -

      -

      39

      39

      5

      44

      Balance at June 30, 2023

      3

      11,756

      (52)

      190

      11,117

      23,014

      152

      23,166










      Balance at January 1, 2024

      3

      11,731

      (44)

      474

      10,744

      22,908

      162

      23,070

      Total comprehensive income

      -

      -

      -

      (77)

      63

      (14)

      8

      (6)

      Dividend

      -

      (414)

      -

      -

      (248)

      (662)

      (3)

      (665)

      Options / performance shares granted

      -

      -

      -

      15

      -

      15

      -

      15

      Options / performance shares vested /
      canceled 

      -

      -

      -

      (25)

      25

      -

      -

      -

      Repurchase / cancellation of shares

      -

      -

      (157)

      -

      -

      (157)

      -

      (157)

      Reissued shares

      -

      -

      52

      -

      (32)

      20

      -

      20

      Changes in non-controlling interests

      -

      -

      -

      -

      -

      -

      (1)

      (1)

      Remuneration on deeply subordinated fixed
      rate resettable perpetual notes

      -

      -

      -

      -

      -

      -

      -

      -

      Other changes

      -

      (4)

      -

      -

      14

      10

      -

      10

      Balance at June 30, 2024

      3

      11,313

      (149)

      387

      10,566

      22,120

      166

      22,286

      Condensed consolidated interim balance sheet at June 30


      in € millions

      June 30
      2024

      December 31
      2023

      Assets



      Goodwill and intangible assets

      18,197

      18,738

      Property, plant and equipment

      5,474

      5,549

      Deferred tax assets

      337

      228

      Share in associates and joint ventures

      163

      130

      Derivatives

      59

      46

      Other non-current assets

      797

      735

      Non-current assets

      25,027

      25,426

      Inventories

      3,405

      3,390

      Trade receivables

      2,771

      2,553

      Income tax receivables

      182

      107

      Other receivables

      142

      183

      Derivatives

      21

      42

      Financial investments

      116

      107

      Cash and cash equivalents

      970

      2,456

      Sub-total

      7,607

      8,838

      Assets held for sale

      176

      6

      Current assets

      7,783

      8,844

      Total assets

      32,810

      34,270




      Equity and liabilities



      Shareholders' equity

      22,120

      22,908

      Non-controlling interest

      166

      162

      Equity

      22,286

      23,070

      Deferred tax liabilities

      1,702

      1,751

      Employee benefit liabilities

      456

      520

      Provisions

      110

      142

      Borrowings

      3,610

      4,114

      Derivatives

      6

      8

      Other non-current liabilities

      104

      146

      Non-current liabilities

      5,988

      6,681

      Employee benefit liabilities

      32

      49

      Provisions

      20

      34

      Borrowings

      972

      716

      Derivatives

      27

      28

      Trade payables

      2,208

      2,071

      Income tax payables

      302

      177

      Other current liabilities

      947

      1,436

      Sub-total

      4,508

      4,511

      Liabilities held for sale

      28

      8

      Current liabilities

      4,536

      4,519

      Total equity and liabilities

      32,810

      34,270

      Condensed consolidated interim cash flow statement


      in € millions

      H1 2024

      H1 2023¹

      Cash and cash equivalents (at beginning of period)

      2,456

      2,755

      Operating activities



      Net profit for the period

      50

      2,375²

      Share of profit of associates and joint ventures

      2

      -

      Income tax expenses

      59

      8

      Profit before tax 

      111

      2,383

      Finance income and expense

      46

      78

      Operating profit

      157

      2,461

      Depreciation, amortization and impairments

      689

      688

      EBITDA

      846

      3,149

      Changes in working capital

      (179)

      (105)

      Income tax

      (122)

      (100)

      Other cash provided by / used in operating activities

      (65)

      (2,651)

      Cash provided by operating activities

      480

      293

      Investing activities



      Payments for intangible assets and property, plant and equipment

      (337)

      (322)

      Acquisition of subsidiaries

      (5)

      (3,619)

      Disposal of subsidiaries

      (59)

      3,608

      Proceeds from disposal of other non-current assets

      5

      (1)

      Change in short-term financial investments

      (9)

      (272)

      Interest received

      15

      27

      Dividend received and capital (re)payments

      (1)

      (4)

      Other cash from / used in investing activities

      (24)

      15

      Cash used in investing activities

      (415)

      (568)

      Financing activities



      Dividends paid

      (664)

      (6)

      Interest paid

      (26)

      (21)

      Repurchase of shares

      (468)

      (256)

      Proceeds from (re)issued treasury shares

      20

      754

      Change in commercial paper

      150

      -

      Proceeds from / repayment of corporate bonds

      (500)

      -

      Payment of lease liabilities

      (53)

      (34)

      Proceeds from / repayment of debt to credit institutions

      10

      18

      Other cash from / used in financing activities

      (47)

      (20)

      Cash (used in) / from financing activities

      (1,578)

      435

      Change in cash and cash equivalents

      (1,513)

      160

      Exchange differences relating to cash held

      27

      (17)

      Cash and cash equivalents at June 30

      970

      2,898


      1 The condensed consolidated interim cash flow statement includes an analysis of all cash flows in total, therefore including both continuing and discontinued operations.

      2 Refers to net profit total group, which includes both continuing and discontinued operations. Net profit of continuing operations is -€412 million.

      Notes to the condensed consolidated interim financial statements

      Note 1 - General Information

      dsm-firmenich Group

      dsm-firmenich is domiciled in Switzerland with the seat of the principal in Kaiseraugst (Switzerland) and listed on Euronext Amsterdam. These condensed consolidated interim financial statements comprise DSM-Firmenich AG and its subsidiaries (the 'Group').

      Basis of preparation

      The accounting policies applied in these interim financial statements are the International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). These consolidated interim financial statements have been prepared in accordance with IAS 34 "Interim Financial Reporting" and should be read in conjunction with the accounting policies as included in the Integrated Annual Report 2023.

      New or amended IFRS that became effective on or after 1 January 2024 did not have a significant impact on the interim financial statements of dsm-firmenich.

      The comparative numbers included in these condensed consolidated interim financial statements include the combined results of the Group as of the date of the merger between DSM and Firmenich, 8 May 2023.

      Audit

      The condensed consolidated interim financial statements and other reported data in this press release have not been audited.

      Seasonality

      The Group operates in markets where generally no significant seasonal or cyclical variations in revenue are experienced during the financial year. However, in cases where businesses are significantly affected by seasonal or cyclical fluctuations in sales, this is discussed in the business review sections earlier in this report.

      Note 2 - Alternative performance measures

      In presenting and discussing dsm-firmenich's financial position, operating results and net results, management uses certain Alternative performance measures not defined by IFRS. These Alternative performance measures (APMs) should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.

      The main APM adjustments in the first half of 2024 are listed below:

      • Acquisition (merger) and divestments costs of €86 million, mainly related to integration costs from the merger of DSM and Firmenich, and the sale of Jiangshan Vitamin C business
      • Restructuring costs of €44 million, mainly related to the vitamin transformation program
      • Impairments of Property, Plants and Equipment (PPE), goodwill, and intangible assets of €94 million, mainly related to the impairment of the Marine Lipids business

      The below table provides a reconciliation of the APMs to the most directly reconcilable IFRS metric for the first half of the reporting period. 

      in € millions

      H1 2024

      H1 2023

      Operating profit (EBIT)

      157

      (371)

      Depreciation, amortization and impairments

      689

      688

      EBITDA

      846

      317

      Acquisitions/divestments 

      86

      160

      Restructuring 

      29

      95

      Other

      15

      23

      Total APM adjustments to EBITDA

      130

      278

      Adj. EBITDA

      976

      595




      Operating profit (EBIT)

      157

      (371)

      APM adjustments to EBITDA

      130

      278

      Impairments of PPE and Intangible assets

      94

      274

      Total APM adjustments to operating profit (EBIT)

      224

      552

      Adj. operating profit (EBIT)

      381

      181

      PPA adjustments dsm-firmenich

      144

      42

      Core adjusted EBIT

      525

      223




      Net profit from continuing operations

      50

      (412)

      APM adjustments to operating profit (EBIT)

      224

      552

      APM adjustments to financial income and expense 

      -

      6

      Income tax related to APM adjustments

      (28)

      (67)

      APM adjustments to share of the profit of associates/jointly controlled entities

      -

      -

      Total APM adjustments to net profit from continuing operations

      196

      491

      Adj. Net profit from continuing operations

      246

      79

      PPA adjustments dsm-firmenich

      119

      38

      Core adj. net profit from continuing operations

      365

      117




      Net profit continuing operations available to holders of ordinary shares

      42

      (426)

      Total APM adjustments to net profit from continuing operations

      196

      491

      Adj. Net profit continuing operations available to holders of ordinary shares

      238

      65

      PPA adjustments dsm-firmenich

      119

      38

      Core adj. net profit continuing operations available to holders of ordinary shares

      357

      103


      H1 2024

      H1 2023


       Continuing
      operations 

       Total
        

       Continuing
      operations 

       Total
        

      Earnings per share (EPS)





      Average number of ordinary shares outstanding (x million)

      265.0

      265.0

      200.6

      200.6






      x € million





      Net profit available to holders of ordinary shares

      42

      42

      (426)

      2,361

      Adj. net profit available to holders of ordinary shares

      238

      238

      65

      66

      Core adj. net profit available to holders of ordinary shares

      357

      357

      103

      104






      in €





      Basic EPS

      0.16

      0.16

      (2.12)

      11.77

      Adj. EPS

      0.90

      0.90

      0.32

      0.33

      Core adj. EPS

      1.35

      1.35

      0.51

      0.52

      in € millions

      H1 2024

      H1 2023

      Adjusted EBITDA

      976

      595

      Change working capital, total group

      (179)

      (105)

      Capital expenditures, total group

      (337)

      (322)

      Excluding discontinued operations

      -

      (55)

      Adj. gross operating free cash flow

      460

      113

      Note 3 - Change in the scope of consolidation

      Acquisitions

      In the first half of 2024, dsm-firmenich finalized the purchase price allocations (PPAs) related to the merger between DSM and Firmenich and the acquisition of Adare Biome without any changes in relation to the PPAs as disclosed in the Integrated Annual Report 2023.

      Divestments

      Divestments in the first half of 2024 resulted in a total (net) loss of €37 million.

      Assets and liabilities held for sale

      On 12 June 2024, dsm-firmenich announced an agreement to sell its yeast extract business to Lesaffre, a key global player in fermentation and micro-organisms. This business is part of dsm-firmenich's Taste, Texture & Health business unit. In addition, dsm-firmenich announced on 18 July 2024 the sale of its fish oil business to KD Pharma Group SA (see also Note 8 - Events after the balance sheet date). The fish oil business is part of dsm-firmenich's Health, Nutrition & Care business unit. The assets and liabilities related to the sale of both these businesses met the criteria for classification as held for sale at the end of the reporting period. Therefore, the assets and liabilities are classified as held for sale.

      The impact of the reclassification of these activities on the dsm-firmenich consolidated balance sheet is presented in the following table.

      in € millions

      June 30, 2024

      Assets


      Non-current assets


      Property, plant & equipment

      33

      Current assets


      Inventories

      138

      Receivables and other current assets

      5

      Total assets

      176

      Liabilities


      Non-current liabilities

      -

      Current liabilities

      28

      Total Liabilities

      28

      Net assets

      148

      Note 4 – Segment Information

      Operating segments

      dsm-firmenich is organized into four distinct Business Units, which have been identified as the reportable operating segments of dsm-firmenich:

      • Perfumery & Beauty (P&B) creates premium scents with proven benefits, using the best and largest palette of natural, synthetic, and biotech ingredients.
      • Taste, Texture & Health (TTH) helps customers create food and beverage products that are delicious, nutritious, affordable, and sustainable. Providing enjoyment and nourishment for consumers, business success for customers, and better health for people and planet.
      • Health, Nutrition & Care (HNC) provides people a way to look after their health by adding critical nutrients to their diet. Driving medical innovation forward, speeding up recovery, and enhancing quality of life.
      • Animal Nutrition & Health (ANH) delivers healthy animal proteins efficiently and sustainably, harnessing power of data to make animal farming practices more sustainable, productive, and transparent.

      Any consolidated activities outside the four reportable operating segments above are reported as the reportable segment 'Corporate Activities'. These consist of corporate operating and service activities that are not further allocated to the operating segments.

      x € millions

      Perfumery &
      Beauty

      Taste,
      Texture &
      Health

      Health,
      Nutrition &
      Care

      Animal
      Nutrition &
      Health

      Corporate
      Activities

      Total
      continuing
      operations

      Discontinued
      operations

      Total

      H1 2023









      Net sales

      788

      962

      1,119

      1,572

      29

      4,470

      46

      4,516

      Adj. EBITDA¹

      175

      170

      208

      85

      (43)

      595

      (2)

      593

      Adj. operating profit¹

      103

      74

      93

      (19)

      (70)

      181

      (2)

      179

      Adj. EBITDA margin (in %)

      22.2

      17.7

      18.6

      5.4

      -

      13.3

      -

      13.1










      H1 2024









      Net sales

      2,007

      1,632

      1,091

      1,536

      32

      6,298

      -

      6,298

      Adj. EBITDA¹

      454

      309

      173

      87

      (47)

      976

      -

      976

      Adj. operating profit¹

      266

      141

      78

      (26)

      (78)

      381

      -

      381

      Adj. EBITDA margin (in %)

      22.6

      18.9

      15.9

      5.7

      -

      15.5

      -

      15.5


      1 A reconciliation between the Alternative performance measures (APMs) and the most directly reconcilable IFRS metric can be found in Note 2 to the Condensed consolidated interim financial statements.

      Geographical information



      Switzer-
      land

      Nether-
      lands

      Rest of
      EMEA

      North
      America

      Latin
      America

      China

      Rest of
      Asia

      Total

      H1 2023









      Net sales (by destination)









      In € millions

      84

      199

      1,283

      1,023

      717

      422

      742

      4,470

      In %

      2

      4

      29

      23

      16

      9

      17

      100










      Workforce at year-end (headcount)

      3,647

      1,849

      7,846

      4,264

      3,617

      4,664

      3,480

      29,367

      Intangible assets and property, plant and
      equipment at year-end (carrying amount)

      15,474

      1,665

      3,147

      2,600

      506

      612

      283

      24,287










      H1 2024









      Net sales (by destination)









      In € millions

      102

      231

      1,930

      1,466

      905

      526

      1,138

      6,298

      In %

      2

      4

      31

      23

      14

      8

      18

      100










      Workforce at period-end (headcount)

      3,658

      1,760

      7,895

      4,279

      3,587

      3,384

      3,363

      27,926

      Intangible assets and property, plant and
      equipment at period-end (carrying amount)

      15,015

      1,679

      3,118

      2,515

      466

      592

      286

      23,671

      Note 5 – Financial Instruments

      The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy. It does not include fair value information for the financial assets and financial liabilities measured at amortized cost if the carrying amount is a reasonable approximation of the fair value.

      For methods and assumptions used to determine the fair value as well as information on the fair value hierarchy used, please refer to the Integrated Annual Report 2023.                                                                              

      in € millions

      Carrying amount

      Fair value¹

      Amortized
      cost

      Fair value
      of hedging
      instr.

      Fair value
      through
      Profit & 
      Loss

      Fair value
      Other
      Compreh.
      Income

      Total

      Level 1

      Level 2

      Level 3

      Total

      Assets at December 31, 2023










      Non-current derivatives

      -

      2

      44

      -

      46

      -

      46

      -

      46

      Other participating interests

      -

      -

      -

      576

      576

      467

      78

      31

      576

      Non-current loans to associates and JVs

      11

      -

      -

      -

      11





      Other non-current receivables

      104

      -

      -

      -

      104





      Trade receivables

      2,553

      -

      -

      -

      2,553





      Other current receivables

      183

      -

      -

      -

      183





      Current derivatives

      -

      42

      -

      -

      42

      -

      42

      -

      42

      Current investments

      107

      -

      -

      -

      107





      Cash and cash equivalents

      1,526

      -

      931

      -

      2,456

      931

      -

      -

      931

      Liabilities at December 31, 2023










      Non-current borrowings

      (4,114)

      -

      -

      -

      (4,114)

      (3,482)

      -

      -

      (3,482)

      Non-current derivatives

      -

      (3)

      (5)

      -

      (8)

      -

      (3)

      (5)

      (8)

      Other non-current liabilities

      (101)

      -

      (45)

      -

      (146)

      -

      -

      (45)

      (45)

      Current borrowings

      (716)

      -

      -

      -

      (716)

      (498)

      -

      -

      (498)

      Current derivatives

      -

      (28)

      -

      -

      (28)

      -

      (28)

      -

      (28)

      Trade payables

      (2,071)

      -

      -

      -

      (2,071)





      Other current liabilities

      (1,436)

      -

      -

      -

      (1,436)















      Assets at June 30, 2024










      Non-current derivatives

      -

      4

      55

      -

      59

      -

      59

      -

      59

      Other participating interests

      -

      -

      -

      570

      570

      465

      78

      27

      570

      Non-current loans to associates and JVs

      11

      -

      -

      -

      11





      Other non-current receivables

      216

      -

      -

      -

      216





      Trade receivables

      2,771

      -

      -

      -

      2,771





      Other current receivables

      142

      -

      -

      -

      142





      Current derivatives


      21



      21

      -

      21

      -

      21

      Current investments

      116

      -

      -

      -

      116





      Cash and cash equivalents

      970

      -

      -

      -

      970





      Liabilities at June 30, 2024










      Non-current borrowings

      (3,610)

      -

      -

      -

      (3,610)

      (3,439)

      -

      -

      (3,439)

      Non-current derivatives

      -

      (4)

      (2)

      -

      (6)

      -

      (4)

      (2)

      (6)

      Other non-current liabilities

      (88)

      -

      (16)

      -

      (104)

      -

      -

      (16)

      (16)

      Current borrowings

      (972)

      -

      -

      -

      (972)

      (490)

      -

      -

      (490)

      Current derivatives

      -

      (27)

      -

      -

      (27)

      -

      (27)

      -

      (27)

      Trade payables

      (2,208)

      -

      -

      -

      (2,208)





      Other current liabilities

      (947)

      -

      -

      -

      (947)





      1 Level 1: Quoted prices in active markets for identical assets or liabilities

      Level 2: Other techniques for which all inputs that have a significant effect on the fair value are observable, either directly or indirectly

      Level 3: Techniques that use inputs that have a significant effect on the fair value that are not based on observable market data

      Note 6 – Related-party transactions

      dsm-firmenich purchased and sold goods and services to various related parties in the first half of 2024. dsm-firmenich has identified its key management personnel and its associates and joint ventures as related parties. Within dsm-firmenich, the members of the Board of Directors and the Members of the Executive Committee of dsm-firmenich meet the definition of key management personnel.

      There were no material changes in the related-party transactions in the first half year of 2024, compared to the transactions as included in the Integrated Annual Report 2023.

      Note 7 – Contingent Liabilities

      Compared to the situation as disclosed in its integrated annual report as at 31 December 2023, dsm-firmenich has not identified any changes to its contingent liabilities.

      Note 8 – Events after the balance sheet date

      On July 2, 2024, DSM B.V. issued bonds, guaranteed by DSM-Firmenich AG, in the amount of €800 million at an issue price of 99.456%. The EUR bonds 2024-2034 have a fixed interest rate of 3.625% and are listed on the Luxembourg Stock Exchange regulated market.

      On 18 July 2024, dsm-firmenich announced the sale of its MEG-3® fish oil business to KD Pharma Group SA ("KD Pharma"), a contract development and manufacturing organization active in pharmaceutical and nutritional lipids. As part of the transaction, dsm-firmenich will obtain a minority stake of 29% in KD Pharma's parent company O³ Holding GmbH. This transaction is expected to be completed towards the end of 2024, and is subject to customary regulatory approvals.

      Financial calendar

      October 31, 2024, 7:00 CET – publication of dsm-firmenich Q3 2024 trading update

      February 13, 2025, 7:00 CET – publication of dsm-firmenich FY 2024 results

      Additional information

      Today dsm-firmenich will hold a webcast for investors and analysts at 9 am CEST. Details on how to access this call can be found on the dsm-firmenich website, www.dsm-firmenich.com.

      For more information

      Media relations

      Investor relations

      Robin Roothans

      Dave Huizing

      tel. +41 (0)79 280 0396

      tel. +31 (0)45 578 2864

      e-mail media@dsm-firmenich.com

      e-mail investors@dsm-firmenich.com

      About dsm-firmenich

      As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss-Dutch company, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life™ every day, everywhere, for billions of people. www.dsm-firmenich.com

      Forward-looking statements
      This press release contains forward-looking statements with respect to dsm-firmenich's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

      PDF - https://mma.prnewswire.com/media/2471358/Presentation_to_Investors_dsm_firmenich_H1_2024_FINAL.pdf

      Logo - https://mma.prnewswire.com/media/2071772/4834808/dsm_firmenich_Logo.jpg

      The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.